The Los Altos-based biotechnology firm confirmed that the regulator’s decision centers solely on its contract manufacturer rather than the drug's clinical performance. According to the company, the FDA has not raised objections regarding safety or efficacy data, nor has it requested additional clinical testing.
In section Market Quotes
Unicycive Therapeutics Shares Slump Following FDA Rejection
A 46% premarket drop hit Unicycive Therapeutics on Tuesday after the FDA issued a second rejection for its lead drug candidate, oxylanthanum carbonate. The agency declined to approve the treatment for dialysis patients, citing unresolved manufacturing deficiencies at an external facility that previously halted the application.
Although Unicycive signaled significant progress toward manufacturing compliance late last year, the company admitted the FDA has yet to perform a fresh inspection of the vendor. Executives remain in discussions with regulators regarding the drug's labeling and packaging. Unicycive management expressed optimism that a future facility inspection will clear the path for an expedited resubmission of their application.
Comments (0)
No comments yet. Be the first!